The future of cystic fibrosis care: a global perspective

Lancet Respiratory Medicine,the
8, 65-124
DOI: 10.1016/s2213-2600(19)30337-6

Citation Report

#	Article	IF	Citations
1	Succinate links mitochondria to deadly bacteria in cystic fibrosis. Annals of Translational Medicine, 2019, 7, S263-S263.	0.7	2
2	A patient's experience of cystic fibrosis care. Lancet Respiratory Medicine,the, 2020, 8, 14-16.	5.2	3
3	Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1193-1208.	2.5	137
4	Transition to adult care in cystic fibrosis: The challenges and the structure. Paediatric Respiratory Reviews, 2022, 41, 23-29.	1.2	5
5	Changing landscape: psychological care in the era of cystic fibrosis transmembrane conductance regulator modulators. Current Opinion in Pulmonary Medicine, 2020, 26, 696-701.	1.2	6
6	Are cystic fibrosis mutation carriers a potentially highly vulnerable group to COVIDâ€19?. Journal of Cellular and Molecular Medicine, 2020, 24, 13542-13545.	1.6	7
7	Comparison of Organoid Swelling and In Vivo Biomarkers of CFTR Function to Determine Effects of Lumacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1589-1592.	2.5	23
8	Cystic fibrosis in Turkey. Lancet Respiratory Medicine,the, 2020, 8, e17.	5.2	2
9	The changing demography of the cystic fibrosis population: forecasting future numbers of adults in the UK. Scientific Reports, 2020, 10, 10660.	1.6	14
11	Molluscan Compounds Provide Drug Leads for the Treatment and Prevention of Respiratory Disease. Marine Drugs, 2020, 18, 570.	2.2	10
12	Emerging Alternatives to Conventional Clinic Visits in the Era of COVID-19: Adoption of Telehealth at VCU Adult Cystic Fibrosis Center . International Journal of General Medicine, 2020, Volume 13, 1175-1186.	0.8	22
13	First Wave of COVID-19 in French Patients with Cystic Fibrosis. Journal of Clinical Medicine, 2020, 9, 3624.	1.0	33
14	The Lung Microbiome of Three Young Brazilian Patients With Cystic Fibrosis Colonized by Fungi. Frontiers in Cellular and Infection Microbiology, 2020, 10, 598938.	1.8	8
15	Observations of, and Insights into, Cystic Fibrosis Mucus Heterogeneity in the Pre-Modulator Era: Sputum Characteristics, DNA and Glycoprotein Content, and Solubilization Time. Journal of Respiration, 2020, 1, 8-29.	0.4	6
16	Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis. The Cochrane Library, 0, , .	1.5	1
17	Lung function deterioration in school children with cystic fibrosis. Pediatric Pulmonology, 2020, 55, 3030-3038.	1.0	3
18	Impact of Cross-Coupling Reactions in Drug Discovery and Development. Molecules, 2020, 25, 3493.	1.7	125
19	Cystic fibrosis â€“ Ten promising therapeutic approaches in the current era of care. Expert Opinion on Investigational Drugs, 2020, 29, 1107-1124.	1.9	8

#	Article	IF	Citations
20	Selectively targeting key inflammatory pathways in cystic fibrosis. European Journal of Medicinal Chemistry, 2020, 206, 112717.	2.6	10
22	ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies. European Respiratory Journal, 2020, 56, 2000946.	3.1	33
23	The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients. Journal of Cystic Fibrosis, 2020, 19, 880-887.	0.3	38
24	Managing Cystic Fibrosis in Polish Healthcare. International Journal of Environmental Research and Public Health, 2020, 17, 7630.	1.2	12
25	Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis. Frontiers in Pharmacology, 2020, 11, 576293.	1.6	5
26	Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis. Trends in Molecular Medicine, 2020, 26, 1068-1077.	3.5	7
27	The Role of Extended CFTR Gene Sequencing in Newborn Screening for Cystic Fibrosis. International Journal of Neonatal Screening, 2020, 6, 23.	1.2	16
28	From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. International Journal of Molecular Sciences, 2020, 21, 5882.	1.8	57
29	Healthcare reassessment in a pandemics time: challenges for CF. Journal of Cystic Fibrosis, 2020, 19, 194-195.	0.3	4
30	Carriers of a single CFTR mutation are asymptomatic: an evolving dogma?. European Respiratory Journal, 2020, 56, 2002645.	3.1	5
31	Airway Inflammation and Host Responses in the Era of CFTR Modulators. International Journal of Molecular Sciences, 2020, 21, 6379.	1.8	36
32	COVID-19 in adult patients with pre-existing chronic cardiac, respiratory and metabolic disease: a critical literature review with clinical recommendations. Tropical Diseases, Travel Medicine and Vaccines, 2020, 6, 16.	0.9	78
34	The Balance between the Safety of Mother, Fetus, and Newborn Undergoing Cystic Fibrosis Transmembrane Conductance Regulator Treatments during Pregnancy. ACS Pharmacology and Translational Science, 2020, 3, 835-843.	2.5	15
35	The human respiratory tract microbial community structures in healthy and cystic fibrosis infants. Npj Biofilms and Microbiomes, 2020, 6, 61.	2.9	18
36	Respiratory muscle training for cystic fibrosis. The Cochrane Library, 2020, 2020, CD006112.	1.5	5
37	Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases. ERJ Open Research, 2020, 6, 00408-2020.	1.1	18
38	ERS International Congress, Madrid, 2019: highlights from the Paediatric Assembly. ERJ Open Research, 2020, 6, 00063-2020.	1.1	1
39	Impaired Ratio of Unsaturated to Saturated Non-Esterified Fatty Acids in Saliva from Patients with Cystic Fibrosis. Diagnostics, 2020, 10, 915.	1.3	2

#	Article	IF	Citations
40	Making Contrast Material Obsolete: Functional Lung Imaging with MRI. Radiology, 2020, 296, 200-201.	3.6	6
41	Volumetric quantification of lung MR signal intensities using ultrashort TE as an automated score in cystic fibrosis. European Radiology, 2020, 30, 5479-5488.	2.3	12
42	Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update. Current Opinion in Pediatrics, 2020, 32, 384-388.	1.0	20
43	The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes, 2020, 11, 589.	1.0	151
44	Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis. International Journal of Molecular Sciences, 2020, 21, 3353.	1.8	20
45	The Microbiome in Cystic Fibrosis Pulmonary Disease. Genes, 2020, 11, 536.	1.0	63
46	Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population. European Respiratory Journal, 2020, 56, 2000558.	3.1	29
47	Horses for courses: Learning from functional tests of pulmonary health?. Pediatric Pulmonology, 2020, 55, 1855-1858.	1.0	4
48	CFTR modulator therapies â€“ Effect on life expectancy in people with cystic fibrosis. Paediatric Respiratory Reviews, 2022, 42, 3-8.	1.2	26
49	Lipopolymers and lipids from lung surfactants in association with N-acetyl-l-cysteine: Characterization and cytotoxicity. Chemistry and Physics of Lipids, 2020, 231, 104936.	1.5	2
50	Evaluation of Droplet Digital Polymerase Chain Reaction (ddPCR) for the Absolute Quantification of Aspergillus species in the Human Airway. International Journal of Molecular Sciences, 2020, 21, 3043.	1.8	19
51	Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholdersâ€™ consensus view. Journal of Cystic Fibrosis, 2020, 19, 688-695.	0.3	14
52	Building global development strategies for cf therapeutics during a transitional cftr modulator era. Journal of Cystic Fibrosis, 2020, 19, 677-687.	0.3	24
53	The Effect of Sodium Bicarbonate, a Beneficial Adjuvant Molecule in Cystic Fibrosis, on Bronchial Epithelial Cells Expressing a Wild-Type or Mutant CFTR Channel. International Journal of Molecular Sciences, 2020, 21, 4024.	1.8	17
54	New method for rapid and dynamic quantification of elastase activity on sputum neutrophils from patients with cystic fibrosis using flow cytometry. European Respiratory Journal, 2020, 55, 1902355.	3.1	4
55	Re-imagining cystic fibrosis care: next generation thinking. European Respiratory Journal, 2020, 55, 1902443.	3.1	12
56	Ivacaftor for the treatment of cystic fibrosis in children under six years of age. Expert Review of Respiratory Medicine, 2020, 14, 547-557.	1.0	6
57	Constructing a Bioethical Framework to Evaluate and Optimise Newborn Bloodspot Screening for Cystic Fibrosis. International Journal of Neonatal Screening, 2020, 6, 40.	1.2	2

#	Article	IF	Citations
58	Clinical and Genotypical Features of False-Negative Patients in 26 Years of Cystic Fibrosis Neonatal Screening in Tuscany, Italy. Diagnostics, 2020, 10, 446.	1.3	22
59	iPSC-Derived Intestinal Organoids from Cystic Fibrosis Patients Acquire CFTR Activity upon TALEN-Mediated Repair of the p.F508del Mutation. Molecular Therapy - Methods and Clinical Development, 2020, 17, 858-870.	1.8	35
60	Echo Timeâ€Dependence of Observed Lung <scp>T₁</scp> in Patients With Cystic Fibrosis and Correlation With Clinical Metrics. Journal of Magnetic Resonance Imaging, 2020, 52, 1645-1654.	1.9	17
62	At the forefront of cystic fibrosis Basic Science research: 16th ECFS Basic Science Conference. Journal of Cystic Fibrosis, 2020, 19, 169-170.	0.3	1
63	Natural products as modulators of eukaryotic protein secretion. Natural Product Reports, 2020, 37, 717-736.	5.2	31
64	Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA. Journal of Cystic Fibrosis, 2020, 19, 733-741.	0.3	35
65	Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease. Journal of Cystic Fibrosis, 2020, 19, 344-354.	0.3	98
66	Patient acceptance and outcome of mental health screening in Swedish adults with cystic fibrosis. Quality of Life Research, 2020, 29, 1579-1585.	1.5	7
67	Real-world evidence in cystic fibrosis modulator development: Establishing a path forward. Journal of Cystic Fibrosis, 2020, 19, e11-e12.	0.3	3
68	Cystic fibrosis 2019: Year in review. Paediatric Respiratory Reviews, 2020, 35, 95-98.	1.2	4
69	Progress in Model Systems of Cystic Fibrosis Mucosal Inflammation to Understand Aberrant Neutrophil Activity. Frontiers in Immunology, 2020, 11, 595.	2.2	12
70	Salivary Cytokines and Airways Disease Severity in Patients with Cystic Fibrosis. Diagnostics, 2020, 10, 222.	1.3	10
71	Impact of COVID-19 on people with cystic fibrosis. Lancet Respiratory Medicine,the, 2020, 8, e35-e36.	5.2	114
72	Cooperation or Tension? Dyadic Coping in Cystic Fibrosis. Family Process, 2021, 60, 285-298.	1.4	4
73	Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events. Journal of Cystic Fibrosis, 2021, 20, 228-233.	0.3	21
74	Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. Journal of Cystic Fibrosis, 2021, 20, 220-227.	0.3	24
75	Cystic fibrosis in low and middle-income countries (LMIC): A view from four different regions of the world. Paediatric Respiratory Reviews, 2021, 38, 37-44.	1.2	16
76	Population genetics: past, present, and future. Human Genetics, 2021, 140, 231-240.	1.8	5

#	Article	IF	Citations
77	Thymosin alpha 1 exerts beneficial extrapulmonary effects in cystic fibrosis. European Journal of Medicinal Chemistry, 2021, 209, 112921.	2.6	3
78	Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 381-385.	2.5	116
79	Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis. Journal of Cystic Fibrosis, 2021, 20, 243-249.	0.3	35
80	Pulmonary Exacerbations in Adults With Cystic Fibrosis. Chest, 2021, 159, 93-102.	0.4	26
81	The Effect of Self-Efficacy, Social Support and Quality of Life on Readiness for Transition to Adult Care Among Adolescents with Cystic Fibrosis in Turkey. Journal of Pediatric Nursing, 2021, 57, e79-e84.	0.7	5
82	Osteoclastogenesis and sphingosine-1-phosphate secretion from human osteoclast precursor monocytes are modulated by the cystic fibrosis transmembrane conductance regulator. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166010.	1.8	2
83	Defining the Clinical Utility of the Lung Clearance Index. Are We There Yet?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 937-939.	2.5	5
84	Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis. Nature Reviews Microbiology, 2021, 19, 331-342.	13.6	213
85	First description of cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 183.	0.3	4
86	Three months of COVID-19 in a pediatric setting in the center of Milan. Pediatric Research, 2021, 89, 1572-1577.	1.1	4
87	Unsupervised phenotypic clustering for determining clinical status in children with cystic fibrosis. European Respiratory Journal, 2021, 58, 2002881.	3.1	6
88	Diagnosis of cystic fibrosis in adulthood and eligibility for novel CFTR modulator therapy. Postgraduate Medical Journal, 2022, 98, 341-345.	0.9	2
90	Early Diagnosis and Intervention in Cystic Fibrosis: Imagining the Unimaginable. Frontiers in Pediatrics, 2020, 8, 608821.	0.9	11
91	Novel Immunomodulatory Therapies for Respiratory Pathologies. , 2022, , 554-594.		5
92	Introducing the Adult Cystic Fibrosis Series. Chest, 2021, 159, 3-4.	0.4	2
93	Comparison of respiratory pathogen colonization and antimicrobial susceptibility in people with cystic fibrosis bronchiectasis versus non-cystic fibrosis bronchiectasis: a protocol for a systematic review. Systematic Reviews, 2021, 10, 7.	2.5	1
95	Patient and family perspectives regarding the use of telehealth for cystic fibrosis care. Pediatric Pulmonology, 2021, 56, 811-813.	1.0	13
96	Cystic fibrosis in Tuscany: evolution of newborn screening strategies over time to the present. Italian Journal of Pediatrics, 2021, 47, 2.	1.0	4

#	Article	IF	Citations
97	COVID-19 lockdown beneficial effects on lung function in a cohort of cystic fibrosis patients. Italian Journal of Pediatrics, 2021, 47, 12.	1.0	8
98	Physiotherapy service provision in a specialist adult cystic fibrosis service: A pre-post design study with the inclusion of an allied health assistant. Chronic Respiratory Disease, 2021, 18, 147997312110178.	1.0	5
99	Liver Disease in Cystic Fibrosis. , 2021, , 93-113.		0
100	Prospective Evaluation of Aspergillus fumigatus-Specific IgG in Patients With Cystic Fibrosis. Frontiers in Cellular and Infection Microbiology, 2020, 10, 602836.	1.8	8
102	Small Molecule CCR4 Antagonists Protect Mice from Aspergillus Infection and Allergy. Biomolecules, 2021, 11, 351.	1.8	4
103	Rapid Improvement after Starting Elexacaftorâ€“Tezacaftorâ€“Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 64-73.	2.5	139
105	Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion. Journal of Endocrinological Investigation, 2021, 44, 2213-2218.	1.8	20
106	Evaluation of Inflammatory Biomarkers in Iranian Patients with Cystic Fibrosis. Current Respiratory Medicine Reviews, 2021, 16, 184-192.	0.1	1
107	The impact of physical activity and exercise interventions for physical health in people with cystic fibrosis: protocol for a systematic review. Systematic Reviews, 2021, 10, 64.	2.5	3
108	De nouveaux espoirs de traitements dans la mucoviscidose. Actualites Pharmaceutiques, 2021, 60, 46-50.	0.0	0
110	Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives. Antibiotics, 2021, 10, 338.	1.5	50
111	Cystic fibrosis transmembrane conductance regulator modulators for cystic fibrosis: a new dawn?. Archives of Disease in Childhood, 2021, 106, 941-945.	1.0	9
112	Respiratory physiology. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 114-117.	0.2	0
113	CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis. Antioxidants, 2021, 10, 483.	2.2	19
114	Discrete choice experiment (DCE) to quantify the influence of trial features on the decision to participate in cystic fibrosis (CF) clinical trials. BMJ Open, 2021, 11, e045803.	0.8	3
115	MucoviscidoseÂ: un second souffle. Perfectionnement En PÃ©diatrie, 2021, 4, 5-9.	0.0	0
116	Pediatric respiratory medicine. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 104-107.	0.2	0
117	Racially equitable diagnosis of cystic fibrosis using next-generation DNA sequencing: a case report. BMC Pediatrics, 2021, 21, 154.	0.7	4

#	Article	IF	Citations
118	Trainability of Health-Related and Motor Performance Fitness in Adults with Cystic Fibrosis within a 12-Month Partially Supervised Exercise Program. Pulmonary Medicine, 2021, 2021, 1-9.	0.5	6
119	Allergic Reactions to Serine Protease-Like Proteins of Staphylococcus aureus. Frontiers in Immunology, 2021, 12, 651060.	2.2	8
120	Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis. Diabetologia, 2021, 64, 1332-1341.	2.9	16
121	Discovery of CFTR modulators for the treatment of cystic fibrosis. Expert Opinion on Drug Discovery, 2021, 16, 897-913.	2.5	38
122	Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis. Thorax, 2021, 76, 1255-1265.	2.7	24
123	Evaluation of Aerosol Therapy during the Escalation of Care in a Model of Adult Cystic Fibrosis. Antibiotics, 2021, 10, 472.	1.5	14
124	Elexacaftorâ€“tezacaftorâ€“ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation. Current Opinion in Pharmacology, 2021, 57, 81-88.	1.7	12
125	Small Hsps as Therapeutic Targets of Cystic Fibrosis Transmembrane Conductance Regulator Protein. International Journal of Molecular Sciences, 2021, 22, 4252.	1.8	2
126	Prenatal Ultrasound Suspicion of Cystic Fibrosis in a Multiethnic Population: Is Extensive CFTR Genotyping Needed?. Genes, 2021, 12, 670.	1.0	4
127	Remote support by multidisciplinary teams: A crucial means to cope with the psychological impact of the SARSâ€COVâ€2 pandemic on patients with cystic fibrosis and inflammatory bowel disease in Lombardia. International Journal of Clinical Practice, 2021, 75, e14220.	0.8	6
128	A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF. BMC Pulmonary Medicine, 2021, 21, 131.	0.8	17
129	Ophthalmologic manifestations of adult patients with cystic fibrosis. European Journal of Ophthalmology, 2021, , 112067212110087.	0.7	1
130	Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target. Inflammation Research, 2021, 70, 633-649.	1.6	4
131	Temporal trends in healthcare resource use and associated costs of patients with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 88-95.	0.3	9
132	Pseudomonas aeruginosa in bronchiectasis: infection, inflammation, and therapies. Expert Review of Respiratory Medicine, 2021, 15, 649-662.	1.0	19
133	Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. Antibiotics, 2021, 10, 486.	1.5	15
134	Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States. Pulmonary Therapy, 2021, 7, 281-293.	1.1	3
135	Elevated sweat chloride test: is it always cystic fibrosis?. Italian Journal of Pediatrics, 2021, 47, 112.	1.0	2

#	Article	IF	Citations
136	Potential of Intestinal Current Measurement for Personalized Treatment of Patients with Cystic Fibrosis. Journal of Personalized Medicine, 2021, 11, 384.	1.1	9
137	Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis. Genes, 2021, 12, 803.	1.0	6
138	Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study. Journal of Cystic Fibrosis, 2022, 21, 111-114.	0.3	25
139	The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada. Journal of Personalized Medicine, 2021, 11, 382.	1.1	2
140	Between competence and warmth: the remaining place of the physician in the era of artificial intelligence. Npj Digital Medicine, 2021, 4, 85.	5.7	12
141	Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis. The Cochrane Library, 0, , .	1.5	1
142	The application of domestic specialized mixtures for enteral nutrition in children with bronchopulmonary pathology. Russian Pediatric Journal, 2021, 24, 78-85.	0.0	1
143	Enhancing Cystic Fibrosis Immune Regulation. Frontiers in Pharmacology, 2021, 12, 573065.	1.6	11
144	Prevalence of monogenic disease in paediatric patients with a predominant respiratory phenotype. Archives of Disease in Childhood, 2021, , archdischild-2021-322058.	1.0	0
146	Cystic fibrosis. Lancet, The, 2021, 397, 2195-2211.	6.3	316
147	Effects of Lumacaftorâ€“Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis. Annals of the American Thoracic Society, 2021, 18, 971-980.	1.5	65
148	A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1522-1532.	2.5	146
149	The Delivery Challenge of Genome Editing in Human Epithelia. Advanced Healthcare Materials, 2021, 10, e2100847.	3.9	4
150	Sweat Chloride Testing and Nasal Potential Difference (NPD) Are Primary Outcome Parameters in Treatment with Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators. Journal of Personalized Medicine, 2021, 11, 729.	1.1	12
151	2-O, 3-O desulfated heparin (ODSH) increases bacterial clearance and attenuates lung injury in cystic fibrosis by restoring HMGB1-compromised macrophage function. Molecular Medicine, 2021, 27, 79.	1.9	4
152	Diagnostic possibilities of lactase deficiency in children with cystic fibrosis. Russian Pediatric Journal, 2021, 24, 157-162.	0.0	1
153	Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis. Journal of Experimental Pharmacology, 2021, Volume 13, 693-723.	1.5	24
155	Elexacaftorâ€“Tezacaftorâ€“Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype. Antibiotics, 2021, 10, 828.	1.5	14

#	Article	IF	Citations
156	Artificial intelligence in computed tomography for quantifying lung changes in the era of CFTR modulators. European Respiratory Journal, 2022, 59, 2100844.	3.1	16
157	Magnetic Resonance Imaging Detects Progression of Lung Disease and Impact of Newborn Screening in Preschool Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 943-953.	2.5	41
158	Year in Review 2020: Multisystemic impact of cystic fibrosis. Pediatric Pulmonology, 2021, 56, 3110-3119.	1.0	2
159	Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease. Genes, 2021, 12, 1178.	1.0	15
160	CFTR-function and ventilation inhomogeneity in individuals with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 641-647.	0.3	6
161	Association of lung clearance index with survival in individuals with cystic fibrosis. European Respiratory Journal, 2022, 59, 2100432.	3.1	3
162	A new era for people with cystic fibrosis. European Journal of Pediatrics, 2021, 180, 2731-2739.	1.3	40
163	Hypertonic saline in people with cystic fibrosis: review of comparative studies and clinical practice. Italian Journal of Pediatrics, 2021, 47, 168.	1.0	7
164	Apples to apples? Comparative analyses of national CF registries. Thorax, 2022, 77, 112-113.	2.7	0
165	Nutritional status and body composition in children with Cystic Fibrosis. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, 1, 57-69.	0.1	0
166	Triple Therapy for Cystic Fibrosis Phe508delâ€“Gating and â€“Residual Function Genotypes. New England Journal of Medicine, 2021, 385, 815-825.	13.9	140
167	Cystic Fibrosis Transmembrane Conductance Regulator Modulators During Pregnancy: A Case Series. Cureus, 2021, 13, e17427.	0.2	6
168	Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study. European Respiratory Journal, 2022, 59, 2100746.	3.1	5
170	CFTR Modulator Therapy and Its Impact on Lung Transplantation in Cystic Fibrosis. Pulmonary Therapy, 2021, 7, 377-393.	1.1	11
171	Outcome of lung transplantation in cystic fibrosis patients with severe asymmetric chest cavities. JTCVS Open, 2021, 8, 652-663.	0.2	2
172	Role of inflammation and oxidative stress in tissue damage associated with cystic fibrosis: CAPE as a future therapeutic strategy. Molecular and Cellular Biochemistry, 2022, 477, 39-51.	1.4	10
173	Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review. International Journal of Antimicrobial Agents, 2021, 58, 106381.	1.1	16
174	Characterizing medication management and the role of pharmacists in caring for people living with cystic fibrosis: AÂwork system approach. Journal of the American Pharmacists Association: JAPhA, 2021, 61, 547-554.e2.	0.7	5

#	Article	IF	Citations
175	A Useful and Sustainable Role for Nâ€ofâ€1 Trials in the Healthcare Ecosystem. Clinical Pharmacology and Therapeutics, 2022, 112, 224-232.	2.3	25
176	Digital technology for early identification of exacerbations in people with cystic fibrosis. The Cochrane Library, 2021, 2021, .	1.5	1
177	Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10ÂkbC-to-T splicing mutation. Journal of Cystic Fibrosis, 2021, 20, 865-875.	0.3	30
178	Breastfeeding in Cystic Fibrosis: A Systematic Review on Prevalence and Potential Benefits. Nutrients, 2021, 13, 3263.	1.7	2
179	Cystic Fibrosis in two Ghanaian Children. , 0, 2, 167-170.		1
180	Cancer in Cystic Fibrosis: A Narrative Review of Prevalence, Risk Factors, Screening, and Treatment Challenges. Chest, 2022, 161, 356-364.	0.4	18
181	Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis. Future Microbiology, 2021, 16, 1087-1104.	1.0	7
182	Outcomes of early repeat sweat testing in infants with cystic fibrosis transmembrane conductance regulatorâ€related metabolic syndrome/CF screenâ€positive, inconclusive diagnosis. Pediatric Pulmonology, 2021, 56, 3785-3791.	1.0	11
183	Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries. European Respiratory Journal, 2021, 58, 2101487.	3.1	2
184	Aquagenic wrinkling in children under two years of age: Could this be a potential clinical referral tool for cystic fibrosis among non-screened populations?. Journal of Cystic Fibrosis, 2021, 20, e77-e83.	0.3	5
185	A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centres. Journal of Cystic Fibrosis, 2021, 20, 828-834.	0.3	32
186	The impact of modulator therapy in cystic fibrosis on patterns of hospitalization related to age. Results from an analysis of US inpatient episodes 2006â€“2016. Journal of Cystic Fibrosis, 2021, 20, e114-e117.	0.3	1
187	Liver transplant in children and adults with cystic fibrosis: Impact of growth failure and nutritional status. American Journal of Transplantation, 2022, 22, 177-186.	2.6	4
188	Therapeutic pipeline for individuals with cystic fibrosis with mutations nonresponsive to current cystic fibrosis transmembrane conductance regulator modulators. Current Opinion in Pulmonary Medicine, 2021, Publish Ahead of Print, 567-574.	1.2	6
189	Survival and Lung Transplant Outcomes for Individuals With Advanced Cystic Fibrosis Lung Disease Living in the United States and Canada. Chest, 2021, 160, 843-853.	0.4	19
190	Retracing changes in cystic fibrosis understanding and management over the past twenty years. Journal of Cystic Fibrosis, 2022, 21, 3-9.	0.3	3
191	Editorial overview: Respiratory: Pulmonary pharmacologyâ€“The emergence of new treatments in pulmonary medicine is finally providing real therapeutic perspectives. Current Opinion in Pharmacology, 2021, 60, 54-58.	1.7	3
192	Cystic Fibrosis in 2021: â€œThe Times They Are A-Changinâ€• Archivos De Bronconeumologia, 2022, 58, 536-538.	0.4	1

#	Article	IF	Citations
193	Recent advances in polymeric nanostructured ion selective membranes for biomedical applications. Talanta, 2021, 235, 122815.	2.9	15
194	Cystic Fibrosis Therapies. , 2022, , 179-187.		0
195	Environmental Microbial Contamination during Cystic Fibrosis Group-Based Psychotherapy. International Journal of Environmental Research and Public Health, 2021, 18, 1142.	1.2	0
196	Long-term safety and efficacy of lumacaftorâ€“ivacaftor therapy in children aged 6â€“11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. Lancet Respiratory Medicine,the, 2021, 9, 721-732.	5.2	25
197	Mental health history and social barriers impacting caregivers of infants with cystic fibrosis. Pediatric Pulmonology, 2021, 56, 457-464.	1.0	4
198	Hydrophobically modified carbon dots as a multifunctional platform for serum-resistant gene delivery and cell imaging. Biomaterials Science, 2020, 8, 3730-3740.	2.6	19
199	Cystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment. Journal of Pediatric Endocrinology and Metabolism, 2020, 33, 835-843.	0.4	23
200	Cystic fibrosis-associated liver disease in children. Minerva Pediatrica, 2020, 72, 440-447.	2.6	5
201	Update on Respiratory Fungal Infections in Cystic Fibrosis Lung Disease and after Lung Transplantation. Journal of Fungi (Basel, Switzerland), 2020, 6, 381.	1.5	12
202	Research advances in molecular mechanisms underlying the pathogenesis of cystic fibrosis: From technical improvement to clinical applications (Review). Molecular Medicine Reports, 2020, 22, 4992-5002.	1.1	9
203	Telemedicine in cystic fibrosis. Journal of Clinical and Translational Endocrinology, 2021, 26, 100270.	1.0	5
204	Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa. International Journal of Pharmaceutics, 2021, 610, 121160.	2.6	14
205	Renal transplantation in a patient with cystic fibrosis: a changing disease landscape. British Journal of Hospital Medicine (London, England: 2005), 2021, 82, 1-3.	0.2	2
206	The Role of Telehealth Services in Children with Cystic Fibrosis During Coronavirus Disease 2019 Outbreak. Telemedicine Journal and E-Health, 2021, , .	1.6	2
207	Lung Clearance Index in Children with Cystic Fibrosis during Pulmonary Exacerbation. Journal of Clinical Medicine, 2021, 10, 4884.	1.0	12
208	Effects of Tham Nasal Alkalinization on Airway Microbial Communities: A Pilot Study in Non-CF and CF Adults. Annals of Otology, Rhinology and Laryngology, 2022, 131, 1013-1020.	0.6	1
209	Commentary: Expert Opinion to â€œImaging Bronchopulmonary Dysplasiaâ€”A Multimodality Updateâ€• Frontiers in Medicine, 2021, 8, 737724.	1.2	0
210	Risk factors for Pseudomonas aeruginosa airway infection and lung function decline in children with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 45-51.	0.3	8

#	Article	IF	Citations
211	Commentary: Paving the way with visualization of the invisible craftsmanship. JTCVS Open, 2021, , .	0.2	0
212	Improving Outcomes for Patients With Sickle Cell Disease in the United States. JAMA Health Forum, 2021, 2, e213467.	1.0	17
213	Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis. EBioMedicine, 2021, 73, 103660.	2.7	10
214	Quantification of Cystic Fibrosis Lung Disease with Radiomics-based CT Scores. Radiology: Cardiothoracic Imaging, 2020, 2, e200022.	0.9	4
215	Appendicitis in Cystic Fibrosis: A Challenging Diagnosis. Bulletin of the Transilvania University of Brasov Series Vi - Medical Sciences, 2020, 13 (62), 19-26.	0.0	0
216	Leveraging Population Genomics for Individualized Correction of the Hallmarks of Alpha-1 Antitrypsin Deficiency. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 224-246.	0.5	4
217	Molecular Physiology and Pharmacology of the Cystic Fibrosis Transmembrane Conductance Regulator. Physiology in Health and Disease, 2020, , 605-670.	0.2	1
218	Validation of a Spanish version of the Leicester Cough Questionnaire in cystic fibrosis. Chronic Respiratory Disease, 2021, 18, 147997312110369.	1.0	1
219	Clinical characteristics of people with cystic fibrosis and frequent fungal infection. Pediatric Pulmonology, 2022, 57, 152-161.	1.0	8
220	Current evidence on the effect of highly effective CFTR modulation on interleukin-8 in cystic fibrosis. Expert Review of Respiratory Medicine, 2022, 16, 43-56.	1.0	5
221	Role for animal models in understanding essential fatty acid deficiency in cystic fibrosis. Cellular and Molecular Life Sciences, 2021, 78, 7991-7999.	2.4	1
222	A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe. Frontiers in Pharmacology, 2021, 12, 746710.	1.6	5
223	Lung ultrasound for the diagnosis of cystic fibrosis pulmonary exacerbation. BMC Pulmonary Medicine, 2021, 21, 353.	0.8	5
225	Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open, 2020, 10, e039089.	0.8	0
226	Personalised Medicine: implication and perspectives in the field of occupational health. Medicina Del Lavoro, 2020, 111, 425-444.	0.3	7
227	The fractional excretion of sodium in patients with cystic fibrosis treated with oral sodium chloride. American Journal of Clinical and Experimental Urology, 2020, 8, 185-190.	0.4	0
228	Defective Glyoxalase 1 Contributes to Pathogenic Inflammation in Cystic Fibrosis. Vaccines, 2021, 9, 1311.	2.1	1
229	A step back in time: The basics of CF care still matter!. Pediatric Pulmonology, 2022, 57, 597-599.	1.0	1

#	Article	IF	Citations
230	Pulmonary arterial hypertension and CFTR: the paradox of going forward by tacking sideways!. European Respiratory Journal, 2021, 58, 2101839.	3.1	0
231	Rare and Complex Epilepsies from Childhood to Adulthood: Requirements for Separate Management or Scope for a Lifespan Holistic Approach?. Current Neurology and Neuroscience Reports, 2021, 21, 65.	2.0	4
232	Management of Cystic Fibrosis during COVID-19: Patient Reported Outcomes based remote follow-up among CF patients in Denmark â€“ AÂfeasibility study. Journal of Cystic Fibrosis, 2022, 21, e106-e112.	0.3	6
233	Emerging Nonpulmonary Complications for Adults With Cystic Fibrosis. Chest, 2022, 161, 1211-1224.	0.4	2
234	Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 529-539.	2.5	147
236	miR-125b Promotes Colorectal Cancer Migration and Invasion by Dual-Targeting CFTR and CGN. Cancers, 2021, 13, 5710.	1.7	16
237	CFTR limits Fâ€actin formation and promotes morphological alignment with flow in human lung microvascular endothelial cells. Physiological Reports, 2021, 9, e15128.	0.7	1
238	Factors Associated With Clinical Progression to Severe COVID-19 in People With Cystic Fibrosis: A Global Observational Study. SSRN Electronic Journal, 0, , .	0.4	1
239	Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation. BMJ Open, 2020, 10, e039089.	0.8	8
240	Impact of guideline-recommended dietitian assessments on weight gain in infants with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 115-122.	0.3	6
241	Genisteinâ€”Opportunities Related to an Interesting Molecule of Natural Origin. Molecules, 2022, 27, 815.	1.7	15
242	The controversy of drug hypersensitivity in patients with cystic fibrosis and review of the literature. Pediatric Allergy and Immunology, 2022, 33, .	1.1	5
243	Cystic Fibrosis: A Disease in Transformation, yet More Work to Be Done!. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 487-489.	2.5	2
244	The success of the Cystic Fibrosis Registry of Turkey for improvement of patient care. Pediatric Pulmonology, 2022, , .	1.0	4
245	The Role of the Microbiome in Asthma Inception and Phenotype. Respiratory Medicine, 2022, , 85-146.	0.1	1
246	Trends in cystic fibrosis survival over 40 years in South Africa: An observational cohort study. Pediatric Pulmonology, 2022, 57, 908-918.	1.0	5
248	Cystic fibrosis in children: A pediatric anesthesiologistâ€™s perspective. Paediatric Anaesthesia, 2022, 32, 167-173.	0.6	4
249	POINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? Yes. Chest, 2022, 161, 18-20.	0.4	2

#	Article	IF	Citations
251	Physiology and pathophysiology of human airway mucus. Physiological Reviews, 2022, 102, 1757-1836.	13.1	78
252	Worldwide rates of diagnosis and effective treatment for cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 456-462.	0.3	112
253	Lung Ultrasound in Children with Cystic Fibrosis in Comparison with Chest Computed Tomography: A Feasibility Study. Diagnostics, 2022, 12, 376.	1.3	10
254	Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 489-496.	0.3	38
255	Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis. Journal of Personalized Medicine, 2022, 12, 252.	1.1	3
256	A Qualitative Exploration into Experiences and Attitudes Regarding Psychosocial Challenges, Self-compassion, and Mindfulness in a Population of Adults with Cystic Fibrosis. Journal of Clinical Psychology in Medical Settings, 2022, 29, 898-910.	0.8	3
257	Prevalence and Impact of Rheumatologic Pain in Cystic Fibrosis Adult Patients. Frontiers in Medicine, 2021, 8, 804892.	1.2	2
258	Major Decrease in Lung Transplantation for Patients with Cystic Fibrosis in France. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 584-586.	2.5	26
259	N-acetylcysteine (NAC) and Its Role in Clinical Practice Management of Cystic Fibrosis (CF): A Review. Pharmaceuticals, 2022, 15, 217.	1.7	18
260	Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 540-549.	2.5	78
261	â€œThe Stakes Are Higherâ€• Patient and Caregiver Perspectives on Cystic Fibrosis Research and Personalized Medicine. Frontiers in Medicine, 2022, 9, 841887.	1.2	1
262	Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respiratory Medicine,the, 2022, 10, 267-277.	5.2	66
263	Satisfaction and Concerns with Telemedicine Endocrine Care of Patients with Cystic Fibrosis. Telemedicine Reports, 2022, 3, 93-100.	0.5	0
264	The effect of inhaled hypertonic saline on lung structure in children aged 3â€“6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 669-678.	5.2	20
265	The effectiveness of the use of a specialized formula based on hydrolyzed milk protein in children older than 1 year of age with cystic fibrosis. Russian Pediatric Journal, 2022, 25, 12-17.	0.0	0
266	A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators. Pediatric Pulmonology, 2022, 57, 1253-1261.	1.0	13
267	CFTR Modulator Therapy for Rare CFTR Mutants. Journal of Respiration, 2022, 2, 59-76.	0.4	5
268	CaracterizaciÃ³n de niÃ±os y adolescentes con Fibrosis QuÃstica que acuden a un hospital de IV Nivel de AtenciÃ³n del Seguro Social de Paraguay, aÃ±os 2016 a 2019. Pediatria, 2022, 49, 27-32.	0.0	0

#	Article	IF	Citations
269	Oral Glucose Tolerance Test in Patients with Cystic Fibrosis Compared to the Overweight and Obese: A Different Approach in Understanding the Results. Children, 2022, 9, 533.	0.6	3
270	CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis. Cells, 2022, 11, 1243.	1.8	14
271	Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network. Journal of Cystic Fibrosis, 2021, 20, 57-63.	0.3	19
272	A Volatile and Dynamic Longitudinal Microbiome Is Associated With Less Reduction in Lung Function in Adolescents With Cystic Fibrosis. Frontiers in Cellular and Infection Microbiology, 2021, 11, 763121.	1.8	5
273	Prevalence of post-glucose challenge hypoglycemia in adult patients with cystic fibrosis and relevance to the risk of cystic fibrosis-related diabetes. Canadian Journal of Diabetes, 2021, 46, 294-301.e2.	0.4	0
274	Financial impacts of the COVID-19 pandemic on cystic fibrosis care: lessons for the future. Journal of Cystic Fibrosis, 2021, 20, 16-20.	0.3	13
275	Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators. Journal of Personalized Medicine, 2021, 11, 1376.	1.1	8
276	Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies. BMJ Open Respiratory Research, 2021, 8, e000998.	1.2	4
277	Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis. Paediatric Respiratory Reviews, 2021, , .	1.2	10
278	Pancreatic Insufficiency in a Child with p.Gly542* and c.2657+5G>A Heterozygote CFTR: A Case Report. Clinical Medicine and Research, 2022, 20, 46-51.	0.4	0
279	State-of-the-art review of lung imaging in cystic fibrosis with recommendations for pulmonologists and radiologists from the â€œiMAging managEment of cySTic fibROsisâ€•(MAESTRO) consortium. European Respiratory Review, 2022, 31, 210173.	3.0	21
280	Current prices versus minimum costs of production for CFTR modulators. Journal of Cystic Fibrosis, 2022, 21, 866-872.	0.3	21
281	Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series. Journal of Cystic Fibrosis, 2022, 21, 885-887.	0.3	12
282	Overview of CF lung pathophysiology. Current Opinion in Pharmacology, 2022, 64, 102214.	1.7	10
284	Molecular Dynamics and Theratyping in Airway and Gut Organoids Reveal R352Q-CFTR Conductance Defect. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 99-111.	1.4	8
286	Application of Genetic Testing in the Diagnosis of Respiratory Genetic Diseases in Children. Medical Diagnosis, 2022, 12, 95-100.	0.0	1
287	Accounting for population structure in genetic studies of cystic fibrosis. Human Genetics and Genomics Advances, 2022, 3, 100117.	1.0	1
288	Cystic fibrosisâ€•related liver disease is an independent risk factor for mortality and increased health care resource utilization in hospitalized pediatric patients with cystic fibrosis. Pediatric Pulmonology, 2022, 57, 1717-1725.	1.0	4

#	Article	IF	Citations
289	Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 311-320.	2.5	49
290	Improving nutrition in cystic fibrosis: A systematic literature review. Nutrition, 2022, 102, 111725.	1.1	4
291	The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis. Orphanet Journal of Rare Diseases, 2022, 17, 188.	1.2	24
292	Sustained inhibition of ENaC in CF: Potential RNA-based therapies for mutation-agnostic treatment. Current Opinion in Pharmacology, 2022, 64, 102209.	1.7	4
293	Limitations of standard cost-effectiveness methods for health technology assessment of treatments for rare, chronic diseases: a case study of treatment for cystic fibrosis. Journal of Medical Economics, 2022, 25, 783-791.	1.0	3
294	An Update on CFTR Modulators as New Therapies for Cystic Fibrosis. Paediatric Drugs, 2022, 24, 321-333.	1.3	18
295	Complex Presentation of Hao-Fountain Syndrome Solved by Exome Sequencing Highlighting Co-Occurring Genomic Variants. Genes, 2022, 13, 889.	1.0	7
296	How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease be Monitored?. American Journal of Respiratory and Critical Care Medicine, 2022, , .	2.5	2
297	Translational Research in Cystic Fibrosis: From Bench to Beside. Frontiers in Pediatrics, 2022, 10, .	0.9	3
298	Spray dried inhalable ivacaftor co-amorphous microparticle formulations with leucine achieved enhanced in vitro dissolution and superior aerosol performance. International Journal of Pharmaceutics, 2022, 622, 121859.	2.6	6
299	Current state of CFTR modulators for treatment of Cystic Fibrosis. Current Opinion in Pharmacology, 2022, 65, 102239.	1.7	19
300	The negative impact of chronic rhinosinusitis on the health-related quality of life among adult patients with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 800-806.	0.3	3
301	CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France. Cells, 2022, 11, 1769.	1.8	17
302	Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score. Frontiers in Pharmacology, 0, 13, .	1.6	33
303	Depression and anxiety prevalence in people with cystic fibrosis and their caregivers: a systematic review and meta-analysis. Social Psychiatry and Psychiatric Epidemiology, 2023, 58, 287-298.	1.6	10
304	Dietary interventions for managing glucose abnormalities in people with cystic fibrosis. The Cochrane Library, 2022, 2022, .	1.5	0
305	Emerging medicines to improve the basic defect in cystic fibrosis. Expert Opinion on Emerging Drugs, 0, , .	1.0	3
306	Altered Intrinsic Brain Activity in Patients With Toothache Using the Percent Amplitude of a Fluctuation Method: A Resting-State fMRI Study. Frontiers in Neurology, 0, 13, .	1.1	1

#	Article	IF	Citations
307	Time Free From Hospitalization in Children and Adolescents With Cystic Fibrosis: Findings From FEV1, Lung Clearance Index and Peak Work Rate. Frontiers in Pediatrics, 0, 10, .	0.9	1
308	Altered intravenous drug disposition in people living with cystic fibrosis: A metaâ€analysis integrating topâ€down and bottomâ€up data. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 951-966.	1.3	5
309	A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1239-1247.	2.5	13
310	Effects of a Long-Term Monitored Exercise Program on Aerobic Fitness in a Small Group of Children with Cystic Fibrosis. International Journal of Environmental Research and Public Health, 2022, 19, 7923.	1.2	3
311	A Middle East systematic review and meta-analysis of prevalence and antibiotic susceptibility pattern in MRSA Staphylococcus aureus isolated from patients with cystic fibrosis. Journal of Health, Population and Nutrition, 2022, 41, .	0.7	0
312	Effects of the Sex Steroid Hormone Estradiol on Biofilm Growth of Cystic Fibrosis Pseudomonas aeruginosa Isolates. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	2
313	Collaboration between two CF centers; one in USA and one in Turkey before and during CoV2 pandemic. Pediatric Pulmonology, 2022, 57, 2553-2557.	1.0	1
314	The Changing Epidemiology of Cystic Fibrosis. Chest, 2023, 163, 89-99.	0.4	16
315	Assessment of Safety Signals for Aztreonam in Different Age Groups: National and International Drug Safety Monitoring. Safety and Risk of Pharmacotherapy, 2022, 10, 110-117.	0.1	0
316	Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1361-1369.	2.5	50
317	Characterizing CFTR modulated sweat chloride response across the cf population: Initial results from the CHEC-SC study. Journal of Cystic Fibrosis, 2023, 22, 79-88.	0.3	4
318	A New Era for Cystic Fibrosis and CFTR Modulator Trials in Infants. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	0
319	LONG-TERM USE OF INHALED HYPERTONIC SALINE IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS: EXPERIENCE FROM A TERTIARY CARE CENTER IN A LOW AND MIDDLE INCOME COUNTRY. Journal of Ayub Medical College, Abbottabad: JAMC, 2022, 34, .	0.1	0
320	Going the Extra Mile: Why Clinical Research in Cystic Fibrosis Must Include Children. Children, 2022, 9, 1080.	0.6	3
321	Genetic spectrum of Chinese children with cystic fibrosis: comprehensive data analysis from the main referral centre in China. Journal of Medical Genetics, 2023, 60, 310-315.	1.5	1
323	Developing an ecological approach to physical activity promotion in adults with Cystic fibrosis. PLoS ONE, 2022, 17, e0272355.	1.1	3
324	Super resolution microscopy analysis reveals increased Orai1 activity in asthma and cystic fibrosis lungs. Journal of Cystic Fibrosis, 2023, 22, 161-171.	0.3	2
325	Dornase alfa in Cystic Fibrosis: indications, comparative studies and effects on lung clearance index. Italian Journal of Pediatrics, 2022, 48, .	1.0	8

#	Article	IF	Citations
326	Modulators of CFTR protein function in the treatment of cystic fibrosis - a literature review. Journal of Education, Health and Sport, 2022, 12, 358-365.	0.0	0
327	Availability of CFTR modulators in countries of Eastern Europe: The reality in 2022. Journal of Cystic Fibrosis, 2022, , .	0.3	3
328	An optimized protocol for assessment of sputum macrorheology in health and muco-obstructive lung disease. Frontiers in Physiology, 0, 13, .	1.3	6
329	Risk factors for severe COVID-19 in people with cystic fibrosis: A systematic review. Frontiers in Pediatrics, 0, 10, .	0.9	7
330	Competitive fitness of Pseudomonas aeruginosa isolates in human and murine precision-cut lung slices. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	3
331	Biofilm aggregates and the host airway-microbial interface. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	12
332	Frequencies of pathogenic CFTR variants in Greek cystic fibrosis patients with allergic bronchopulmonary aspergillosis and Aspergillus fumigatus chronic colonization: A retrospective cohort study. Journal De Mycologie Medicale, 2022, , 101326.	0.7	0
333	Surgical considerations in cystic fibrosis: what every general surgeon needs to know. ANZ Journal of Surgery, 0, , .	0.3	0
334	Update on the management of vitamins and minerals in cystic fibrosis. Nutrition in Clinical Practice, 2022, 37, 1074-1087.	1.1	13
335	Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis. Journal of Personalized Medicine, 2022, 12, 1321.	1.1	15
336	Challenges and opportunities associated with rare-variant pharmacogenomics. Trends in Pharmacological Sciences, 2022, 43, 852-865.	4.0	14
337	Impact of Pancreatitis-Associated Protein on Newborn Screening Outcomes and Detection of CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A Monocentric Prospective Pilot Experience. International Journal of Neonatal Screening, 2022, 8, 46.	1.2	6
338	Clinical outcomes of digital health in adults with cystic fibrosis. Respiratory Medicine, 2022, 202, 106970.	1.3	0
339	Drug treatment of cystic fibrosis. Australian Prescriber, 2022, 45, 171-175.	0.5	0
340	The Exeter Activity Unlimited statement on physical activity and exercise for cystic fibrosis: methodology and results of an international, multidisciplinary, evidence-driven expert consensus. Chronic Respiratory Disease, 2022, 19, 147997312211216.	1.0	4
341	Pathogenic Variants Spectrum and Allele Frequency of the CFTR Gene in Asians. Allergy, Asthma and Immunology Research, 2022, 14, 444.	1.1	0
342	Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 817-825.	0.6	5
344	Newly Discovered Cutting-Edge Triple Combination Cystic Fibrosis Therapy: A Systematic Review. Cureus, 2022, , .	0.2	5

#	Article	IF	Citations
345	Antimicrobial Stewardship in Cystic Fibrosis. Journal of the Pediatric Infectious Diseases Society, 2022, 11, S53-S61.	0.6	3
346	Physical activity and its correlates in people with cystic fibrosis: a systematic review. European Respiratory Review, 2022, 31, 220010.	3.0	2
347	Body mass index and additional risk factors for cancer in adults with cystic fibrosis. Cancer Causes and Control, 0, , .	0.8	0
348	Progress in Respiratory Gene Therapy. Human Gene Therapy, 2022, 33, 893-912.	1.4	8
349	Springâ€infusors: How a simple and small solution can create kingâ€sized complexity. Nursing Open, 0, , .	1.1	1
350	Thoracic configuration in patients ageing with cystic fibrosis: A retrospective single-blinded cohort study. Respiratory Physiology and Neurobiology, 2022, , 103976.	0.7	0
351	ECFS standards of care on CFTR-related disorders: Diagnostic criteria of CFTR dysfunction. Journal of Cystic Fibrosis, 2022, 21, 922-936.	0.3	18
352	What Makes Pseudomonas aeruginosa a Pathogen?. Advances in Experimental Medicine and Biology, 2022, , 283-301.	0.8	4
353	Pseudomonas aeruginosa Pangenome: Core and Accessory Genes of a Highly Resourceful Opportunistic Pathogen. Advances in Experimental Medicine and Biology, 2022, , 3-28.	0.8	5
354	Characteristics of X-ray pattern of lung lesion in COVID-19 in adult patients with cystic fibrosis. Ukrainian Journal of Radiology and Oncology, 2022, 30, 9-24.	0.2	0
355	Complementary Dual Approach for In Silico Target Identification of Potential Pharmaceutical Compounds in Cystic Fibrosis. International Journal of Molecular Sciences, 2022, 23, 12351.	1.8	1
356	Clinically undetected polyclonal heteroresistance among Pseudomonas aeruginosa isolated from cystic fibrosis respiratory specimens. Journal of Antimicrobial Chemotherapy, 2022, 77, 3321-3330.	1.3	1
358	The Unique Experience of a New Multidisciplinary Program for 22q Deletion and Duplication Syndromes in a Community Hospital in Florida: A Reaffirmation That Multidisciplinary Care Is Essential for Best Outcomes in These Patients. Genes, 2022, 13, 1949.	1.0	2
359	Delivery of RNAs to Specific Organs by Lipid Nanoparticles for Gene Therapy. Pharmaceutics, 2022, 14, 2129.	2.0	15
360	Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis. Journal of Cystic Fibrosis, 2023, 22, 17-30.	0.3	22
361	Clinical Advances in Cystic Fibrosis. Journal of Clinical Medicine, 2022, 11, 6306.	1.0	1
362	Underreporting of patient-reported outcomes in cystic fibrosis randomized controlled trials using CONSORT-PRO and RoB 2.0. Respiratory Medicine and Research, 2023, 83, 100962.	0.4	1
363	Barriers for Sports and Exercise Participation and Corresponding Barrier Management in Cystic Fibrosis. International Journal of Environmental Research and Public Health, 2022, 19, 13150.	1.2	3

#	Article	IF	Citations
364	Chest radiography and computed tomography imaging in cystic fibrosis: current challenges and new perspectives. Pediatric Radiology, 2023, 53, 649-659.	1.1	3
365	Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation. Pulmonary Therapy, 0, , .	1.1	0
366	Challenged Urine Bicarbonate Excretion as a Measure of Cystic Fibrosis Transmembrane Conductance Regulator Function in Cystic Fibrosis. Annals of Internal Medicine, 2022, 175, 1543-1551.	2.0	8
367	Dual CFTR modulator therapy efficacy in the real world: lessons for the future. ERJ Open Research, 2022, 8, 00464-2022.	1.1	3
368	Case report of a pediatric Chinese cystic fibrosis patient with the c.1521_1523delCTT/c.3874â€4522A>G genotype. Pediatric Pulmonology, 2023, 58, 556-558.	1.0	1
369	Lung Cancer Risk Prediction with Machine Learning Models. Big Data and Cognitive Computing, 2022, 6, 139.	2.9	29
370	Clearing up the smoke: Physical and mental health considerations regarding cannabis use in adolescents with cystic fibrosis. Pediatric Pulmonology, 2023, 58, 398-407.	1.0	3
371	Survival of people with cystic fibrosis in Australia. Scientific Reports, 2022, 12, .	1.6	7
372	Cystic fibrosisâ€related mortality trends in Mexico between 1999 and 2020. Pediatric Pulmonology, 2023, 58, 632-634.	1.0	0
373	Characterizing attributes of innovation of technologies for healthcare: a systematic review. Journal of Medical Economics, 2022, 25, 1158-1166.	1.0	2
374	Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis. Clinics in Chest Medicine, 2022, 43, 617-630.	0.8	2
375	Evaluation of the quality of life and associated factors of a group of children and adolescents with cystic fibrosis in the northern region of Portugal: a cross-sectional pilot study. Porto Biomedical Journal, 2022, 7, e194.	0.4	0
376	Mental Health of Cystic Fibrosis Patients and the COVID-19 Pandemic in Poland: A Single-Center Comparative Study. International Journal of Environmental Research and Public Health, 2022, 19, 16056.	1.2	2
377	Cystic fibrosis and bronchiectasis: the risk of cancer and the impact on cancer treatment. , 2022, , 123-133.		0
378	Diagnosis of cystic fibrosis in adults: Australian Cystic Fibrosis Data Registry data, 2000â€“2019. Medical Journal of Australia, 0, , .	0.8	1
379	CRISPR-free, programmable RNA pseudouridylation to suppress premature termination codons. Molecular Cell, 2023, 83, 139-155.e9.	4.5	21
380	CFTR Modulators: Current Status and Evolving Knowledge. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 186-195.	0.8	2
381	Exercise and Airway Clearance Techniques in Cystic Fibrosis. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 209-216.	0.8	2

#	Article	IF	Citations
382	Prebiotics for people with cystic fibrosis. The Cochrane Library, 2022, 2022, .	1.5	1
383	SIMPLIFYing cystic fibrosis treatment in a post-modulator era. Lancet Respiratory Medicine,the, 2023, 11, 299-300.	5.2	1
384	Loss of endothelial CFTR drives barrier failure and edema formation in lung infection and can be targeted by CFTR potentiation. Science Translational Medicine, 2022, 14, .	5.8	5
385	Respiratory Viruses and Cystic Fibrosis. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 196-208.	0.8	1
386	Exercise as an Airway Clearance Technique in people with Cystic Fibrosis (ExACT-CF): rationale and study protocol for a randomised pilot trial. NIHR Open Research, 0, 2, 64.	0.0	0
387	Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background. Journal of Cystic Fibrosis, 2023, 22, 525-537.	0.3	9
388	PECULIARITIES OF CYSTIC FIBROSIS IN NEWBORN ON THE EXAMPLE OF A CLINICAL CASE. Neonatology Surgery and Perinatal Medicine, 2022, 12, 89-93.	0.0	0
389	Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised. Value in Health, 2023, 26, 567-578.	0.1	2
390	Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond. European Respiratory Journal, 2023, 61, 2201307.	3.1	9
391	Challenges and opportunities in the development of novel antimicrobial therapeutics for cystic fibrosis. Journal of Medical Microbiology, 2022, 71, .	0.7	3
393	Antibacterial Activity of a Natural Clay Mineral against Burkholderia cepacia Complex and Other Bacterial Pathogens Isolated from People with Cystic Fibrosis. Microorganisms, 2023, 11, 150.	1.6	7
394	Clinical relevance of low bone density in cystic fibrosis adult patients: A pilot study. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ove	0.4	0
395	TRACK-CF prospective cohort study: Understanding early cystic fibrosis lung disease. Frontiers in Medicine, 0, 9, .	1.2	1
396	Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial. Journal of Cystic Fibrosis, 2023, 22, 464-470.	0.3	2
397	Markov Modelling for Mucoviscidosis using Genomic Data. European Journal of Education and Pedagogy, 2022, 3, 27-34.	0.2	0
398	Magnetic resonance imaging detects onset and association with lung disease severity of bronchial artery dilatation in cystic fibrosis. ERJ Open Research, 2023, 9, 00473-2022.	1.1	4
399	Nutritional Status and Circulating Levels of Fat-Soluble Vitamins in Cystic Fibrosis Patients: A Cohort Study and Evaluation of the Effect of CFTR Modulators. Children, 2023, 10, 252.	0.6	7
400	Lessons from other fields of medicine, Part 2: Cystic fibrosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 119-130.	1.0	1

#	Article	IF	Citations
401	Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis. Life Science Alliance, 2023, 6, e202201857.	1.3	5
402	Transforming the nutrition care model for infants with cystic fibrosis: A qualitative study of clinicians' perspectives. Pediatric Pulmonology, 2023, 58, 1380-1390.	1.0	2
403	Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the â€œFirst in Cystic Fibrosisâ€• Phase I Clinical Trial (CEASE-CF). Pharmaceuticals, 2023, 16, 220.	1.7	3
404	Cystic Fibrosis Transmembrane Conductance Regulator Protein Modulators in Children and Adolescents with Different CF Genotypes - Systematic Review and Meta-Analysis. Current Reviews in Clinical and Experimental Pharmacology, 2024, 19, 93-110.	0.4	1
405	The circadian control of tryptophan metabolism regulates the host response to pulmonary fungal infections. , 2023, 2, .		0
406	Elexacaftor/tezacaftor/ivacaftorâ€”real-world clinical effectiveness and safety. A single-center Portuguese study. Jornal Brasileiro De Pneumologia, 0, , e20220312.	0.4	1
407	Preparation and Characterization of Ibuprofen Containing Nano-Embedded-Microparticles for Pulmonary Delivery. Pharmaceutics, 2023, 15, 545.	2.0	2
408	Future therapies for cystic fibrosis. Nature Communications, 2023, 14, .	5.8	17
409	Cystic Fibrosis: A Descriptive Analysis of Deaths in a Two-Decade Period in Brazil According to Age, Race, and Sex. Diagnostics, 2023, 13, 763.	1.3	4
410	Respiratory Infection and Inflammation in Cystic Fibrosis: A Dynamic Interplay among the Host, Microbes, and Environment for the Ages. International Journal of Molecular Sciences, 2023, 24, 4052.	1.8	3
411	Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy. Expert Review of Respiratory Medicine, 2023, 17, 97-108.	1.0	6
412	Safety and efficacy of vanzacaftorâ€“tezacaftorâ€“deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials. Lancet Respiratory Medicine,the, 2023, 11, 550-562.	5.2	14
413	Risk factors for forced expiratory volume in 1 s decline in European patients with cystic fibrosis: data from the European Cystic Fibrosis Society Patient Registry. ERJ Open Research, 2023, 9, 00449-2022.	1.1	1
414	Cystic Fibrosis Bone Disease: The Interplay between CFTR Dysfunction and Chronic Inflammation. Biomolecules, 2023, 13, 425.	1.8	2
415	Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del. Journal of Cystic Fibrosis, 2023, 22, 607-614.	0.3	29
416	Exhaled breath profiles to detect lung infection with Staphylococcus aureus in children with cystic fibrosis. Journal of Cystic Fibrosis, 2023, 22, 888-893.	0.3	3
418	Inherited causes of exocrine pancreatic insufficiency in pediatric patients: clinical presentation and laboratory testing. Critical Reviews in Clinical Laboratory Sciences, 2023, 60, 366-381.	2.7	1
419	Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators. International Journal of Molecular Sciences, 2023, 24, 5010.	1.8	5

#	Article	IF	Citations
420	Paediatric Lung Transplantation. , 2023, , 525-542.		0
421	Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Pharmaceuticals, 2023, 16, 410.	1.7	17
422	The Cystic Fibrosis Upper and Lower Airway Metagenome. Microbiology Spectrum, 2023, 11, .	1.2	7
423	Sweat conductivity for diagnosing cystic fibrosis after positive newborn screening: prospective, diagnostic test accuracy study. Archives of Disease in Childhood, 2023, 108, 538-542.	1.0	4
424	Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review. Children, 2023, 10, 554.	0.6	9
425	Inequalities in cystic fibrosis. , 2023, , 116-128.		0
426	Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftorâ€"Ivacaftor. Frontiers in Pharmacology, 0, 14, .	1.6	7
427	Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial. Annals of the American Thoracic Society, 2023, 20, 1144-1155.	1.5	3
428	Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study. Journal of Cystic Fibrosis, 2023, 22, 730-737.	0.3	26
429	CF Bridge of Hope program, a global medical home practice. Pediatric Pulmonology, 2023, 58, 1802-1804.	1.0	0
430	Competitive survival of clonal serial Pseudomonas aeruginosa isolates from cystic fibrosis airways in human neutrophils. IScience, 2023, 26, 106475.	1.9	1
432	Real-world disparities and ethical considerations with access to CFTR modulator drugs: Mind the gap!. Frontiers in Pharmacology, 0, 14, .	1.6	14
433	Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis. The Cochrane Library, 2023, 2023, .	1.5	3
434	Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators. International Journal of Molecular Sciences, 2023, 24, 6576.	1.8	3
435	Implementation of standardized cystic fibrosis care algorithm to improve the center data-quality improvement project international collaboration. Journal of Cystic Fibrosis, 2023, , .	0.3	0
436	Antibiotic Therapy for Pulmonary Exacerbations in Cystic Fibrosisâ€"A Single-Centre Prospective Observational Study. Antibiotics, 2023, 12, 734.	1.5	0
437	Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data. PLoS ONE, 2023, 18, e0283479.	1.1	0
438	Digital technology for early identification of exacerbations in people with cystic fibrosis. The Cochrane Library, 2023, 2023, .	1.5	3

#	Article	IF	Citations
439	Survival-Adjusted FEV1 and BMI Percentiles for Patients with Cystic Fibrosis before the Era of Triple CFTR Modulator Therapy in Germany. Respiration, 2023, 102, 1-1.	1.2	0
440	Pediatric Pulmonology Training in India: Current Status and Future Directions. Indian Journal of Pediatrics, 2023, 90, 718-722.	0.3	3
441	Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis. Frontiers in Pharmacology, 0, 14, .	1.6	8
464	Cystic fibrosis and other ion channel-related diseases. , 2023, , 135-149.		0
471	The future is mainstream: genetic counselling should be embedded in mainstream medicine. European Journal of Human Genetics, 0, , .	1.4	0
487	Protein Networks in Human Disease. , 2023, , 1-41.		0
538	Lung Cancer Prediction Using Machine Learning Models. Lecture Notes in Networks and Systems, 2023, , 613-618.	0.5	0
556	A Stacking Approach Based on Machine Learning Techniques for Lungs Cancer Prediction in Healthcare Systems. , 2023, , .		0
560	Fungal Respiratory Colonization and Infections in Cystic Fibrosis Patients in the Middle East. Current Fungal Infection Reports, 2024, 18, 40-50.	0.9	0
569	Multi-Class Classification of Lung Cancer Detection Using Deep Learning Model. Lecture Notes in Networks and Systems, 2024, , 367-377.	0.5	0